NYT today has an excellent long narrative about the clinical trial drug PLX4032.  For some, the drug seems to work very well in eradicating metastatic melanoma.

This article offers a unique inside look into the world of cancer clinical trials.  We often forget about this human aspect of what it takes to be enrolled on a study, and certainly the conference presentations and journal articles don't give us any clue on how researchers struggle with tough decisions and hopeful drugs that once in a while pan out.